Presbia, a medical device producer of near-vision restoration,
reportedly has received a letter from the U.S. Food &
Drug Administration (FDA) indicating that it is being actively
considered for an Investigational Device Exemption (IDE, G120225) for
its Presbia Flexivue Microlens, an implantable corneal
inlay solution for presbyopia, the age-related loss of near vision.Read more.